The global cancer biomarkers market size is expected to reach around US$ 29.8 Bn by 2026 and will grow at noteworthy CAGR of around 11.9% over the forecast period 2019 to 2026.
Cancer biomarker is a substance that helps to indicate the presence of cancer in the body. This substance may be a molecule secreted by a tumor or specific response of the body to a tumor. Genetic, proteomic, and glycomic biomarkers used for various applications such as diagnosis, epidemiology, and prognosis. These are also used in cancer research or drug discovery process field. Biomarkers can be identified in blood, urine, stool, tissue, and other body fluids. Currently, various biomarkers are using for patient care such as BRCA1/BRCA2 (Breast /Ovarian cancer), EGFR (Non-small cell lung carcinoma), HER-2 (Breast cancer), PSA (Prostate cancer), S100 (Melanoma), and AFP (liver cancer). Based on the specific recognition of intracellular and cancerous cell surface biomarkers, various technologies have been developed to identify a tumor in the body. These technologies include immunoassays, cytogenetic testing, omics technology, and imaging technologies such as CT, Ultrasound, MRI, PET, and mammography.
Market Dynamics
Increasing healthcare expenditure, technological advancements which led to high speed and more accuracy, favorable reimbursements in developed countries, and growing awareness about regular health checkups are the major driving factors of the cancer biomarkers market. Additionally, rising number of cancer patients across the world, investment by market players for the development and commercialization of cancer biomarkers, presence of strong pipeline, and increasing affordability of patients for advanced cancer treatment are some of the other factors that propel the market. For instance, according to the World Health Organization (WHO), global burden of cancer reached to 18.1 million new cases and 9.6 million deaths in 2018. Increased in cancer cases were observed due to several factors such as ageing, unhealthy lifestyle, and changing social & economic scenario. High capital investment for research, development, and commercialization, stringent & complex regulatory requirements, and low or no reimbursement in low and middle income countries are key restraining factors of the market. Furthermore, specimen collection and storage, detailed tracking, and retrieval software are necessary for proper management and accurate result. These issues are also anticipated to hinder the overall cancer biomarkers market growth.
Based on type, the cancer biomarkers market has been segmented into protein biomarker, genetic biomarker, and others. Other segment includes viral, cell, and carbohydrate biomarkers. Protein biomarkers accounted for the largest segment in the market in 2018 due to its ability of early diagnosis and presence of several commercial biomarkers.
On the basis of technology used for profiling, the market has been categorized into omics technology, immunoassay, imaging technologies, and cytogenetic testing. The omics technology segment accounted for the largest share of the market in 2018. This can be attributed to revolution in the omics technologies since last decade responsible for the increase in the applications of biomarkers.
Based on the application, prognostics segment held the maximum share of the market in 2018 and is expected to maintain to maintain its dominance during the forecasts period. However, the diagnosis segment is anticipated to witness the fastest growth in coming years.
Based on the cancer type, breast cancer accounted for the largest share of the market due to more awareness about screening, availability of commercialized products, and high sensitivity of markers to detect breast cancer. Lung cancer, colorectal cancer, prostate cancer, leukemia, thyroid gland cancer, kidney cancer, and bladder cancer are some of the other cancers where biomarkers are used for the various applications.
North America dominated the cancer biomarkers market in 2018 due to high ongoing research in the development of cancer biomarkers, mergers & collaborations for the development and commercialization of products, favorable reimbursement for cancer diagnosis & treatment, and awareness about companion diagnostics and personalized medicines. For instance, in January 2017, GeneNews launched a blood-based biomarker test, BreastSentry, for risk assessment of breast cancer in the U.S.
The market research study on “Cancer Biomarkers Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026”, offers a detailed insight on the global cancer biomarkers market entailing insights on its different market segments. Market dynamics with drivers, restraints, and opportunities with their impact are provided in the report. The report provides insights into the global cancer biomarkers market, its type, technology, cancer type, application, and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global cancer biomarkers market size, and segment markets by type, technology, cancer type, application, and geography along with the information on companies operating in the market. The cancer biomarkers market analysis is provided for major regional markets including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. For each region, the market size for different segments has been covered under the scope of the report.
The players profiled in the report include Abbott Laboratories, Agilent Technologies, Becton Dickinson and Company, Hologic, Illumina, Merck & Co., Qiagen N.V., Roche Diagnostics, and Thermo Fisher Scientific. The competitors are involved in the research and development activities, commercialization of sensitive products, and collaborations for the development & commercialization to enhance their market footprints.
Market Segmentation
By Type
By Technology
- Omics Technology
- Immunoassay
- Imaging Technology
- Cytogenetic Testing
By Cancer Type
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Leukemia
- Thyroid gland Cancer
- Kidney Cancer
- Bladder Cancer
- Others
By Application
- Diagnosis
- Prognosis
- Research
- Others
By Geography
- North America
- Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Table Of Content
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Cancer Biomarkers
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Cancer Biomarkers Market By Type
1.2.2.1. Global Cancer Biomarkers Market Revenue and Growth Rate Comparison By Deployment Mode (2015-2026)
1.2.2.2. Global Cancer Biomarkers Market Revenue Share By Deployment Mode in 2018
1.2.2.3. Protein
1.2.2.4. Genetic
1.2.2.5. Others
1.2.3. Cancer Biomarkers Market By Technology
1.2.3.1. Global Cancer Biomarkers Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.3.2. Omics Technology
1.2.3.3. Immunoassay
1.2.3.4. Imaging Technology
1.2.3.5. Cytogenetic Testing
1.2.4. Cancer Biomarkers Market By Cancer Type
1.2.4.1. Global Cancer Biomarkers Market Revenue and Growth Rate Comparison By Deployment Mode (2015-2026)
1.2.4.2. Breast Cancer
1.2.4.3. Lung Cancer
1.2.4.4. Prostate Cancer
1.2.4.5. Colorectal Cancer
1.2.4.6. Leukemia
1.2.4.7. Thyroid gland Cancer
1.2.4.8. Kidney Cancer
1.2.4.9. Bladder Cancer
1.2.4.10. Others
1.2.5. Cancer Biomarkers Market By Application
1.2.5.1. Global Cancer Biomarkers Market Revenue and Growth Rate Comparison By End User (2015-2026)
1.2.5.2. Diagnosis
1.2.5.3. Prognosis
1.2.5.4. Research
1.2.5.5. Others
1.2.6. Cancer Biomarkers Market By Geography
1.2.6.1. Global Cancer Biomarkers Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Cancer Biomarkers Market Revenue and Growth Rate(2015-2026)
1.2.6.3. Europe Cancer Biomarkers Market Revenue and Growth Rate(2015-2026)
1.2.6.4. Asia-Pacific Cancer Biomarkers Market Revenue and Growth Rate(2015-2026)
1.2.6.5. Latin America Cancer Biomarkers Market Revenue and Growth Rate(2015-2026)
1.2.6.6. Middle East and Africa (MEA)Cancer Biomarkers Market Revenue and Growth Rate(2015-2026)
CHAPTER 2. MARKET DYNAMICSAND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Cancer Biomarkers Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Cancer Biomarkers Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Cancer Biomarkers Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Cancer Biomarkers Major Manufacturers in 2018
CHAPTER 4. CANCER BIOMARKERS MARKET BY TYPE
4.1. Global Cancer Biomarkers Revenue By Type
4.2. Protein
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Genetic
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Others
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. CANCER BIOMARKERS MARKET BY TECHNOLOGY
5.1. Global Cancer Biomarkers Revenue By Technology
5.2. Omics Technology
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Immunoassay
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Imaging Technology
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Cytogenetic Testing
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. CANCER BIOMARKERS MARKET BY CANCER TYPE
6.1. Global Cancer Biomarkers Revenue By Cancer Type
6.2. Breast Cancer
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Lung Cancer
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Prostate Cancer
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Colorectal Cancer
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Leukemia
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.7. Thyroid gland Cancer
6.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.8. Kidney Cancer
6.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.9. Bladder Cancer
6.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.10. Others
6.10.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.10.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. CANCER BIOMARKERS MARKET BY APPLICATION
7.1. Global Cancer Biomarkers Revenue By Application
7.2. Diagnosis
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Prognosis
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Research
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.5. Others
7.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 8. NORTH AMERICA CANCER BIOMARKERS MARKET BY COUNTRY
8.1. North America Cancer Biomarkers Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Cancer Biomarkers Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Cancer Biomarkers Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
8.3.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
8.4.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 9. EUROPE CANCER BIOMARKERS MARKET BY COUNTRY
9.1. Europe Cancer Biomarkers Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Cancer Biomarkers Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
9.3.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
9.4.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
9.5.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
9.6.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
9.7.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 10. ASIA-PACIFIC CANCER BIOMARKERS MARKET BY COUNTRY
10.1. Asia-Pacific Cancer Biomarkers Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Cancer Biomarkers Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
10.3.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
10.4.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
10.5.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.6.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
10.6.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.7.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
10.7.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.8.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
10.8.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 11. LATIN AMERICA CANCER BIOMARKERS MARKET BY COUNTRY
11.1. Latin America Cancer Biomarkers Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Cancer Biomarkers Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
11.3.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.4. Mexico
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
11.4.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
11.5.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 12. MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET BY COUNTRY
12.1. Middle East & Africa Cancer Biomarkers Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East & Africa Cancer Biomarkers Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. GCC
12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
12.3.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.4. South Africa
12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
12.4.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.5. Rest of Middle East & Africa
12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
12.5.4. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 13. COMPANY PROFILE
13.1. Abbott Laboratories
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Agilent Technologies
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Becton Dickinson and Company.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Hologic
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Illumina
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Merck & Co.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Qiagen N.V.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Optum, Inc.
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Roche Diagnostics
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Thermo Fisher Scientific
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies
13.11. Others
13.11.1. Company Snapshot
13.11.2. Overview
13.11.3. Financial Overview
13.11.4. Type Portfolio
13.11.5. Key Developments
13.11.6. Strategies
CHAPTER 14. RESEARCH APPROACH
14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope
